Close

Gilead’s drug remdesivir gets US FDA’s emergency use authorisation for COVID-19

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Gilead was granted EUA by U.S. FDA for the investigational antiviral remdesivir to treat COVID-19. The EUA will facilitate broader use of remdesivir to treat hospitalized patients with severe COVID-19 disease, enabling access to remdesivir at additional hospitals across the country. Allocation of the currently limited available supply of remdesivir will be made based on guiding principles that aim to maximize access for appropriate patients in urgent need of treatment, with direction from and in collaboration with the government.

The optimal duration of treatment is still being studied in ongoing clinical trials. Under the EUA, both 5-day and 10-day treatment durations are suggested, based on the severity of disease. The authorization is temporary and does not take the place of the formal new drug application submission, review and approval process. The EUA allows for the distribution and emergency use of remdesivir only for the treatment of COVID-19; remdesivir remains an investigational drug and has not been approved by FDA.

The U.S. government will coordinate the donation and distribution of remdesivir to hospitals in cities most heavily impacted by COVID-19. Gilead is working with the U.S. government on the logistics of remdesivir distribution and will provide more information when the company begins shipping the drug under the EUA.

The EUA is based on available data from two global clinical trials – the National Institute for Allergy and Infectious Diseases’ placebo-controlled Phase III study in patients with moderate to severe symptoms of COVID-19, including those who were critically ill, and Gilead’s global Phase III study evaluating 5-day and 10-day dosing durations of remdesivir in patients with severe disease.

As previously announced, Gilead has donated the entirety of its existing supply of finished and unfinished product to help address the urgent medical needs posed by this pandemic around the world. Assuming a 10-day treatment course, Gilead’s donation of 1.5 million individual doses of remdesivir equates to more than 140,000 treatment courses that will be provided at no cost.

Latest stories

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back